Peginterferon alfa-2b

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Peginterferon alfa-2b
Clinical data
Trade names PegIntron, Sylatron, ViraferonPeg, others
AHFS/Drugs.com Professional Drug Facts
MedlinePlus a605030
Pregnancy
category
  • C, X (with ribavirin)
Routes of
administration
subQ
ATC code
Pharmacokinetic data
Biological half-life 22–60 hrs
Identifiers
CAS Number
IUPHAR/BPS
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard 100.208.164
Chemical and physical data
Formula C860H1353N229O255S9
Molar mass 19269.1 g/mol
 NYesY (what is this?)  (verify)

Pegylated interferon alfa-2b, sold under the brand name is PegIntron among others, is a medication used to treat hepatitis C and melanoma.[1] For hepatitis C it is typically used with ribavirin and cure rates are between 33 and 82%.[1][2] For melanoma it is used in addition to surgery.[1] It is given by injection under the skin.[1]

Side effects are common.[3] They may include headache, feeling tired, mood changes, trouble sleeping, hair loss, nausea, pain at the site of injection, and fever.[1] Severe side effects may include psychosis, liver problems, blood clots, infections, or an irregular heartbeat.[1] Use with ribavirin is not recommended during pregnancy.[1] Pegylated interferon alfa-2b is in the alpha interferon family of medications.[1] It is pegylated to protects the molecule from breakdown.[3]

Pegylated interferon alfa-2b was approved for medical use in the United States in 2001.[1] It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system.[4] The wholesale cost in the developing world is between 500 and 4,800 USD for 12 weeks.[5] In the United States this costs about 8,400.00 USD,[3] while in the United Kingdom 12 weeks costs the NHS about 1595.00 pounds.[6]

Medical uses[edit]

It is used to treat hepatitis C and melanoma. For hepatitis C it is typically used with ribavirin. For melanoma it is used in addition to surgery.[1]

For hepatitis C it may also be used with boceprevir, telaprevir, simeprevir, or sofosbuvir.[3]

Host genetic factors[edit]

For genotype 1 hepatitis C treated with pegylated interferon-alfa-2a or pegylated interferon-alfa-2b combined with ribavirin, it has been shown that genetic polymorphisms near the human IL28B gene, encoding interferon lambda 3, are associated with significant differences in response to the treatment. This finding, originally reported in Nature,[7] showed that genotype 1 hepatitis C patients carrying certain genetic variant alleles near the IL28B gene are more likely to achieve sustained virological response after the treatment than others. A later report from Nature[8] demonstrated that the same genetic variants are also associated with the natural clearance of the genotype 1 hepatitis C virus.

Side effects[edit]

Common side effects include headache, feeling tired, mood changes, trouble sleeping, hair loss, nausea, pain at the site of injection, and fever. Severe side effects may include psychosis, liver problems, blood clots, infections, or an irregular heartbeat.[1] Use with ribavirin is not recommended during pregnancy.[1]

Mechanism of action[edit]

One of the major mechanisms of PEG-interferon alpha-2b utilizes the JAK-STAT signaling pathway. The basic mechanism works such that PEG-interferon alpha-2b will bind to its receptor, interferon-alpha receptor 1 and 2 (IFNAR1/2). Upon ligand binding the Tyk2 protein associated with IFNAR1 is phosphorylated which in turn phosphorylates Jak1 associated with IFNAR2. This kinase continues its signal transduction by phosphorylation of signal transducer and activator of transcription (STAT) 1 and 2 via Jak 1 and Tyk2 respectively. The phosphorylated STATs then dissociate from the receptor heterodimer and form an interferon transcription factor with p48 and IRF9 to form the interferon stimulate transcription factor-3 (ISGF3). This transcription factor then translocates to the nucleus where it will transcribe several genes involved in cell cycle control, cell differentiation, apoptosis, and immune response.[9][10]

PEG-interferon alpha-2b acts as a multifunctional immunoregulatory cytokine by transcribing several genes, including interleukin 4 (IL4). This cytokine is responsible for inducing T helper cells to become type 2 helper T cells. This ultimately results in the stimulation of B cells to proliferate and increase their antibody production. This ultimately allows for an immune response, as the B cells will help to signal the immune system that a foreign antigen is present.[11]

Another major mechanism of type I interferon alpha (IFNα) is to stimulate apoptosis in malignant cell lines. Previous studies have shown that IFNα can cause cell cycle arrest in U266, Daudi, and Rhek-1 cell lines.[12]

A follow-up study researched to determine if the caspases were involved in the apoptosis seen in the previous study as well as to determine the role of mitochondrial cytochrome c release. The study confirmed that there was cleavage of caspase-3, -8, and -9. All three of these cysteine proteases play an important role in the initiation and activation of the apoptotic cascade. Furthermore, it was shown that IFNα induced a loss in the mitochondrial membrane potential which resulted in the release of cytochrome c from the mitochondria. Follow-up research is currently being conducted to determine the upstream activators of the apoptotic pathway that are induced by IFNα.[13]

History[edit]

It was developed by Schering-Plough. Merck studied it for melanoma under the brand name Sylatron. It was approved for this use in April 2011.

References[edit]

  1. ^ a b c d e f g h i j k l "Peginterferon Alfa-2b (Professional Patient Advice) - Drugs.com". www.drugs.com. Archived from the original on 16 January 2017. Retrieved 12 January 2017. 
  2. ^ "ViraferonPeg Pen 50, 80, 100, 120 or 150 micrograms powder and solvent for solution for injection in pre-filled pen CLEAR CLICK - Summary of Product Characteristics (SPC) - (eMC)". www.medicines.org.uk. Archived from the original on 13 January 2017. Retrieved 12 January 2017. 
  3. ^ a b c d "Peginterferon alfa-2b (PegIntron) - Treatment - Hepatitis C Online". www.hepatitisc.uw.edu. Archived from the original on 23 December 2016. Retrieved 12 January 2017. 
  4. ^ "WHO Model List of Essential Medicines (19th List)" (PDF). World Health Organization. April 2015. Archived (PDF) from the original on 13 December 2016. Retrieved 8 December 2016. 
  5. ^ "Inclusion of the injectable formulation of peginterferon alfa-2a and -2b is proposed for the treatment of hepatitis C among adults." (PDF). who.int. p. 11. Archived (PDF) from the original on 13 January 2017. Retrieved 12 January 2017. 
  6. ^ British national formulary : BNF 69 (69 ed.). British Medical Association. 2015. p. 639. ISBN 9780857111562. 
  7. ^ Ge D, Fellay J, Thompson AJ, et al. (2009). "Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance". Nature. 461 (7262): 399–401. PMID 19684573. doi:10.1038/nature08309. 
  8. ^ Thomas DL, Thio CL, Martin MP, et al. (2009). "Genetic variation in IL28B and spontaneous clearance of hepatitis C virus". Nature. 461 (7265): 798–801. PMC 3172006Freely accessible. PMID 19759533. doi:10.1038/nature08463. 
  9. ^ Ward AC, Touw I, Yoshimura A (January 2000). "The Jak-Stat pathway in normal and perturbed hematopoiesis". Blood. 95 (1): 19–29. PMID 10607680. 
  10. ^ PATHWAYS :: IFN alpha
  11. ^ Thomas H, Foster G, Platis D (February 2004). "Corrigendum to ‘‘Mechanisms of action of interferon and nucleoside analogues’’ J Hepatol 39 (2003) S93–8". J Hepatol. 40 (2): 364. doi:10.1016/j.jhep.2003.12.003. 
  12. ^ Sangfelt O, Erickson S, Castro J, Heiden T, Einhorn S, Grandér D (March 1997). "Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines". Cell Growth Differ. 8 (3): 343–52. PMID 9056677. Archived from the original on 2014-04-26. 
  13. ^ Thyrell L, Erickson S, Zhivotovsky B, et al. (February 2002). "Mechanisms of Interferon-alpha induced apoptosis in malignant cells". Oncogene. 21 (8): 1251–62. PMID 11850845. doi:10.1038/sj.onc.1205179. 

External links[edit]